![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Scheen André J
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.13, Iss.1, 2012-01, pp. : 139-146
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical Drug Investigation, Vol. 32, Iss. 3, 2012-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Saxagliptin shows promise for type 2 diabetes
Inpharma, Vol. 1, Iss. 1642, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Saxagliptin: A New Drug for the Treatment of Type 2 Diabetes
Mini Reviews in Medicinal Chemistry, Vol. 10, Iss. 8, 2010-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Saxagliptin: a guide to its use in type 2 diabetes mellitus
Drugs & Therapy Perspectives, Vol. 26, Iss. 8, 2010-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Add-on therapies to metformin for type 2 diabetes
Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. :